- Home
- EDIT vs PBH Comparison
EDIT vs PBH Comparison
Compare EDIT & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- PBH
- Stock Information
- Founded
- EDIT 2013
- PBH 1996
- Country
- EDIT United States
- PBH United States
- Employees
- EDIT N/A
- PBH N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- PBH Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- PBH Health Care
- Exchange
- EDIT Nasdaq
- PBH Nasdaq
- Market Cap
- EDIT N/A
- PBH 4.1B
- IPO Year
- EDIT 2016
- PBH 2005
- Fundamental
- Price
- EDIT $1.45
- PBH $87.25
- Analyst Decision
- EDIT Buy
- PBH Buy
- Analyst Count
- EDIT 15
- PBH 5
- Target Price
- EDIT $7.69
- PBH $94.00
- AVG Volume (30 Days)
- EDIT 1.7M
- PBH 351.3K
- Earning Date
- EDIT 05-16-2025
- PBH 05-08-2025
- Dividend Yield
- EDIT N/A
- PBH N/A
- EPS Growth
- EDIT N/A
- PBH 2.88
- EPS
- EDIT N/A
- PBH 4.29
- Revenue
- EDIT $32,314,000.00
- PBH $1,137,762,000.00
- Revenue This Year
- EDIT N/A
- PBH $1.48
- Revenue Next Year
- EDIT N/A
- PBH $2.28
- P/E Ratio
- EDIT N/A
- PBH $20.29
- Revenue Growth
- EDIT N/A
- PBH 1.10
- 52 Week Low
- EDIT $0.91
- PBH $62.35
- 52 Week High
- EDIT $6.69
- PBH $90.04
- Technical
- Relative Strength Index (RSI)
- EDIT 51.06
- PBH 63.14
- Support Level
- EDIT $1.29
- PBH $80.62
- Resistance Level
- EDIT $1.73
- PBH $84.90
- Average True Range (ATR)
- EDIT 0.15
- PBH 2.16
- MACD
- EDIT -0.01
- PBH 0.75
- Stochastic Oscillator
- EDIT 36.36
- PBH 92.23
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.